ZURICH/ LONDON, Oct 22 - Roche ROPC.S sales rose in the third quarter, the Swiss drugmaker said on Thursday, slightly beating analyst expectations.
With growth in both its pharmaceuticals and diagnostics divisions, group sales came in at 16.13 billion Swiss francs ($19.61 billion), slightly above average analyst expectations of 15.75 billion Swiss francs in a company compiled consensus.
Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
